New blog posts

Over the web Recharges - Increase the main advantages of Your Prepaid Arrange
Over the web Recharges - Increase the main advantages of Your Prepaid Arrange

5 December, 2021 by bunnybunny

No stipulations submit an application In...

Around the net Recharges - Greatly enhance the advantages Your Prepaid Schedule
Around the net Recharges - Greatly enhance the advantages Your Prepaid Schedule

5 December, 2021 by bunnybunny

No conditions and terms make use of In...

How often should I have to inspect my tyres?

4 December, 2021 by Drift Tyres

There are many...

View all blog entries →

Magic Mushrooms for Depression? The Pros & Cons

Posted on 5 October, 2021 by Edward Jack

Magic Mushrooms for Depression? The Pros & Cons

Psilocybin, a psychedelic drug included in Magic Mushrooms, is a regular prescription drug with a variety of secondary measures, similar to the antidepressants commonly used to relieve the symptoms of major depression. It exceeds. The results of a small phase II trial show.


A 6-week study of 59 patients with moderate to severe depression found the effects of high doses of psilocybin and the selective serotonin reuptake inhibitor (SSRI) sold under the Lexapro brand name. There was no significant difference from the effects of escitalopram.


Patients in the thyrosibin-treated group showed much faster improvement in key measurements of depression than patients receiving escitalopram, but until this gap became statistically insignificant. , Narrowed during the research period.


"It is very clear that psychedelic therapy is started with antidepressants faster than escitalopram, and psychedelics were consistently superior in side effects, but there was no difference in primary. "The lead author, Dr. Robin Carhart Harris, and Psychedelic Research at Center Imperial College London, told reporters at a press conference.


The results of the Phase II, double-blind, randomized trial were published online in the New England Journal of Medicine on April 15.


Secondary results

Researchers have found that psilocybin defeats escitalopram with several secondary consequences, including well-being, the ability to express emotions, and social functioning.


Still, the team warned that no conclusions could be drawn from these secondary measures because of the need for larger and longer studies.


Fifty-nine patients were randomly assigned to Mushroom Strains and 29 patients were assigned to escitalopram. Each step was mirrored in both groups.


All patients received oral psilocybin on two "dosing days" scheduled during the 6-week study. However, the escitalopram group received 1 milligram, while the urinal group received 25 milligrams.


"And the reason we did that is because we can standardize our expectations. We tell everyone that you have psilocybin. Only the dosage can be different." Said Carhart-Harris.


He admitted that most, if not all, patients were able to determine which group they belonged to after the first day of administration, based on the effectiveness of the drug.


After oral administration, the volunteers spent six hours in a bed supported by two "guides" or therapists, surrounded by pillows and carefully selected music. The guide was on hand to support the patient during the psychedelic experience, but did not speak or interfere.


The next day, the patients attended a session with two therapists to discuss their experiences.


During the day of administration, patients in the high-dose silosibine group were taking capsules containing placebo daily. The low dose group took a course of escitalopram.

1 October, 2021

9 September, 2021

9 June, 2021

6 April, 2021

5 April, 2021

16 August, 2018

27 October, 2018

4 November, 2019

25 October, 2017

14 January, 2020